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DBackground: Surgical and catheter-based interventions on pulmonary veins are associated with pulmonary vein
stenosis (PVS), which can progress diffusely through the ‘‘upstream’’ pulmonary veins. The mechanism has
been rarely studied. We used a porcine model of PVS to assess disease progression with emphasis on the
potential role of endothelial-mesenchymal transition (EndMT).
Methods: Neonatal piglets underwent bilateral pulmonary vein banding (banded, n ¼ 6) or sham operations
(sham, n ¼ 6). Additional piglets underwent identical banding and stent implantation in a single-banded
pulmonary vein 3 weeks postbanding (stented, n ¼ 6). At 7 weeks postbanding, hemodynamics and upstream
PV pathology were assessed.
Results: Banded piglets developed pulmonary hypertension. The upstream pulmonary veins exhibited intimal
thickening associated with features of EndMT, including increased transforming growth factor (TGF)-b1 and
Smad expression, loss of endothelial and gain of mesenchymal marker expression, and coexpression of
endothelial and mesenchymal markers in banded pulmonary vein intimal cells. These immunopathologic
changes and a prominent myofibroblast phenotype in the remodeled pulmonary veins were consistently
identified in specimens from patients with PVS, in vitro TGF-b1-stimulated cells isolated from piglet and human
pulmonary veins, and human umbilical vein endothelial cells. After stent implantation, decompression of a
pulmonary vein was associated with reappearance of endothelial marker expression, suggesting the potential
for plasticity in the observed pathologic changes, followed by rapid in-stent restenosis.
Conclusions: Neonatal pulmonary vein banding in piglets recapitulates critical aspects of clinical PVS and
highlights a pathologic profile consistent with EndMT, supporting the rationale for evaluating therapeutic
strategies designed to exploit reversibility of upstream pulmonary vein pathology. (J Thorac Cardiovasc Surg
2014;148:245-53)Pulmonary vein stenosis (PVS) can occur as either a primary
congenital or an acquired disease after repair of total anom-
alous pulmonary venous drainage (TAPVD).1-3 A unique
characteristic of PVS is the potential for progressive and
diffuse stenosis throughout the pulmonary venous system.
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The Journal of Thoracic and Capulmonary vein–left atrial junction, the most malignant
form of the disease is characterized by diffuse involvement
of the ‘‘upstream’’ pulmonary veins extending into the lung
parenchyma. With the diffuse upstream lesion, PVS leads
to relentless pulmonary hypertension, right heart failure,
and death. Despite scattered recent reports of catheter-
based interventions and surgical procedures,4,5 the overall
prognosis is poor.6-9 Remarkably, the cellular mechanisms
and pathophysiology that cause upstream PVS remain
incompletely explored.
To investigate the cellular mechanisms associated with
PVS, we used a neonatal piglet model previously estab-
lished by LaBourene and colleagues,10 with the objective
of examining the histopathology of upstream PVS to char-
acterize the diffuse fibrogenic response in the pulmonary
veins. Our results suggest that endothelial-mesenchymal
transition (EndMT) contributes to the propagation of the
disease into the upstream pulmonary veins. By using
cellular markers of EndMT, we characterized the disease
process in the piglet model and found correlative data
derived from pulmonary vein cell culture systems andrdiovascular Surgery c Volume 148, Number 1 245
Abbreviations and Acronyms
EndMT ¼ endothelial-mesenchymal transition
FSP ¼ fibroblastic-specific protein
GAPDH ¼ glyceraldehyde-3-phosphate
dehydrogenase
HCI ¼ high-content imaging
HE ¼ hematoxylin and eosin
HUVEC ¼ human umbilical vein endothelial cell
PVS ¼ pulmonary vein stenosis
SMA ¼ smooth muscle actin
TAPVD ¼ total anomalous pulmonary venous
drainage
TGF ¼ transforming growth factor
VE ¼ vascular endothelial
vWF ¼ von Willebrand factor VIII
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Dautopsy-derived human specimens. Consistent with prior
reports,9 pulmonary vein stenting to relieve obstruction
was associated with rapid in-stent restenosis. However,
we observed evidence of regression of the pathologic pro-
cess in the upstream pulmonary veins after stenting, sug-
gesting an element of reversibility at the cellular level and
highlighting new avenues of investigation.
METHODS
Research Ethics Board Approval
The Animal Care Committee at the Hospital for Sick Children approved
the animal studies in accordancewith the Terms of Reference following the
Canadian Council on Animal Care Guidelines and federal/provincial
legislations. Human samples were acquired with approval of the Research
Ethics Board protocols under the auspices of the Heart Centre Biobank
Registry (No. 1000011232 and No. 0020010432).
Piglet Pulmonary Vein Stenosis Model
One-week-old Yorkshire piglets (3.9  0.8 kg) underwent staged
bilateral pulmonary vein banding (banded, n ¼ 6) or sham operations
(sham, n ¼ 6). After anesthesia and intubation, piglets underwent staged
operations, as previously described.10 Banding of left pulmonary veins
and the common lower pulmonary vein was performed via a left fifth
intercostal space thoracotomy, followed by banding of right pulmonary
veins 1 week later, using one-eighth inch–wide cotton umbilical tapes
with a length equivalent to 1.3 times the pulmonary vein circumference.
Sham–operated on piglets underwent identical banding procedures, but
the band was not left in place.
Echocardiography was performed under anesthesia before banding/
sham operation and at 3 and 6 weeks postprocedure. At 7 weeks after
bilateral banding/sham procedures, the piglets were anesthetized and in-
strumented to monitor hemodynamic parameters using 5F thermodilution
catheters (Teleflex, Limerick, Pa). Cardiac output was determined by
injection of 23  1C saline (5 mL) into the main pulmonary artery and
calculated with a cardiac output computer (model 9520A; Edwards Life-
sciences, Irvine, Calif). Lung biopsy specimens were taken from each
left distal middle lobe. The heart and lungs were quickly removed en
bloc and dissected on a bed of ice. The upstream pulmonary veins were ob-
tained, excluding pulmonary veins within the first 10 mm from banded
sites, and divided into sections for the primary cell culture, fixed in 10%
formalin, or frozen. Hematoxylin and eosin (HE) staining was used to246 The Journal of Thoracic and Cardiovascular Surgshow the intimal thickness and pulmonary vein morphology. Intimal thick-
ness was assessed by measurement of the ratio of intimal to intimal þ
medial layer thickness at 8 radial points in each pulmonary vein.
Stent Implantation
Another 6 piglets were allotted for stent treatment (stented, n ¼ 6).
Three weeks after identical bilateral pulmonary vein banding with the
banded group, the stented group underwent placement of bare-metal stents
(Driver; Medtronic Inc, Minneapolis, Minn) into the right middle
pulmonary vein via femoral vein catheterization with 8F sheaths under
fluoroscopic and intracardiac echocardiographic guidance (8F AcuNav
catheter; Biosense Webster, Diamond Bar, Calif). After atrial septum
puncture with a pediatric transseptal needle (COOK, Bloomington, Ind),
using a 6F RunWay WRP guide catheter (Boston Scientific Corp, Natick,
Mass), bare-metal stents (3.5- or 4.0-mm in diameter) were deployed
into the banding site of the right middle pulmonary vein. Acetylsalicylic
acid, 10 mg/kg per day (Tanta Pharmaceuticals Inc, Whitby, Ontario,
Canada), and clopidogrel, 2.5 mg/kg per day (Teva Canada, Ontario,
Canada), were given orally until the end point of the study. At 7 weeks post-
banding, invasive hemodynamics were measured and tissues were excised,
as previously described. The stented portions of the pulmonary veins were
excised and cross-sectioned at 3 points within the stent (proximal, middle,
and distal) cut by an Isomet slow-speed saw (Buehler, Lake Bluff, Ill) and
tungsten carbide knife. The percentage of in-stent restenosis was
quantified using Image J software (National Institutes of Health,
Bethesda, MD), according to the following formula: 100 3 (ICM [minus]
LA)/ICM, where ICM is the inner area of the internal circumference of the
media and LA is the inner area of internal circumference of the intima.11-13
Human Tissue
Pulmonary vein specimens were obtained from 3 patients with PVS.
One patient had recurrent PVS after TAPVD repair (2 days of age),
followed by reoperation for progressive PVS (3 months of age) and
subsequent death. Autopsy specimens were stained for immunofluores-
cence, as described later (Figure 1,C-G). A second patient, with a diagnosis
of tetralogy of Fallot and PVS, underwent intracardiac repair and pulmo-
nary vein stent implantation at the age of 17 months. However, subsequent
in-stent restenosis and severe pulmonary hypertension resulted in death at
the age of 20 months. At autopsy, Movat pentachrome staining was
performed to assess the PV morphology in 1 patient (Figure 1, A). A third
patient, diagnosed with hypoplastic left heart syndrome, had recurrent
refractory PVS after heart transplant at the age of 5 months and died at
the age of 9 months. Elastic Masson trichrome staining of the pulmonary
veins was used at autopsy (Figure 1, B).
Control human pulmonary vein tissues were obtained from a heart trans-
plant donor who was 2 months old and did not have pulmonary vascular
disease; they were analyzed using the same immunofluorescence protocols
(Figure 1, H-L) and cultured for high-content imaging (HCI) analysis.
Right Ventricle Cellular Size and Myocardial
Fibrosis
Transmural blocks of the right ventricularmyocardiumwere fixed in 10%
formalin, divided into sections, and stained with HE and Masson trichrome
stains.14 Randomly selected high-power fields (4003, 60 fields per piglet)
from right ventricular free walls were examined for analysis of cellular size
and cardiac fibrosis. The diameter of cells was determined by measuring
the distance across the cell at its narrowest plane, including the nucleus (Im-
age J software). The area of myocardial collagen content for each field was
quantified (Photoshop CS4; Adobe Systems, San Jose, Calif) as a percentage
of the entire slide and averaged.
Immunofluorescence
Paraffin-embedded tissue slides were deparaffinized in xylene and
rehydrated in ethanol. Antigens were remasked with sodium citrate bufferery c July 2014
FIGURE 1. Histology and immunofluorescence staining in human and piglet pulmonary veins. A, Human pulmonary vein histology from a patient with
pulmonary vein stenosis (PVS); Movat pentachrome staining showed fibromuscular hyperplasia. B, Human PVS lung tissue; elastic trichrome staining
demonstrated marked pulmonary vein intimal hyperplasia (arterialization) with luminal narrowing. C-G, Pulmonary veins from a total anomalous
pulmonary venous drainage (TAPVD) patient with PVS (4003 magnification) compared with the control histology. H-L, Control pulmonary veins from
a heart transplant donor without PVS; endothelial markers (CD31 and von Willebrand factor [vWF] in D and E) were decreased, and expression of
transforming growth factor (TGF)-b1 (C) and mesenchymal markers (fibronectin and a-smooth muscle actin [SMA] in F and G) were increased in the
TAPVD patient, consistent with the piglet study. M-P, Hematoxylin and eosin staining of upstream pulmonary veins in the piglet model. M and N,
Sham group. O and P, Banded group. Banded PVs had increased intimal thickness (red arrows in P). Intimal thickness as percentage of intimal þ medial
layer thickness was greater in banded pulmonary veins. *P<.05. Q and R, Representative microvascular changes in the lung. Q, Lung tissue in the sham
group had thin-walled pulmonary veins. R, Lung tissue in the banded group had intimal hyperplasia in pulmonary veins.
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D(Dako, Glostrup, Denmark), then immersed in blocking buffer for
40 minutes and incubated with primary antibodies CD31 (1:100; Abcam,
Cambridge, UK), fibronectin (1:200; BD Transduction Laboratories,
Franklin Lakes, NJ), vascular endothelial cadherin (VE-cadherin, 1:100;
Thermo Fisher Scientific, Waltham, Mass), a-smooth muscle actin
(a-SMA, 1:100; Santa Cruz Biotechnology, Santa Cruz, Calif),
fibroblastic-specific protein 1 (FSP-1)/S100A4 (1:100;Millipore, Billerica,
Mass), von Willebrand factor VIII (vWF, 1:100; Dako), and transforming
growth factor (TGF)-b1 (1:100; Abcam) for 2 hours at room temperature,
followed by the secondary anti-rabbit antibody (1:1000) and anti-mouse
fluorescein isothiocyanate (1:100) for 1 hour at room temperature. Slides
were visualized using a QuorumWaveFX-X1 Spinning Disc Confocal Sys-
tem (Quorum Technologies, Guelph, Ontario, Canada) and Volocity soft-
ware (PerkinElmer Inc, Waltham, Mass).
Protein Extraction and Western Blot Analysis
Upstream PV samples from piglets were homogenized in lysis buffer
and centrifuged for 20 minutes at 13,400g at 4C, and the supernatantsThe Journal of Thoracic and Cawere collected. Protein extracts were quantified with a Bradford protein
assay (Bio-Rad, Hercules, Calif).
Samples were separated on 10% polyacrylamide gels, transferred to
nitrocellulose membranes, and blocked with 5% skimmed milk for 1
hour. The membranes were probed with CD31 (1:1000), VE-cadherin
(1:1000), a-SMA (1:1000), TGF-b1 (1:1000), Smad4 (1:500; Abcam),
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 1:6000;
Sigma-Aldrich, St Louis, Mo). Blots were then incubated with goat anti-
mouse IgG horseradish peroxidase (1:10,000) and goat anti-rabbit IgG
horseradish peroxidase (1:5000) secondary antibodies. Membranes were
developed with electrochemiluminescence substrate (Santa Cruz Biotech-
nology). Densitometry was analyzed using Quantity One and Image Lab
analysis software (Bio Rad Laboratories, Hercules, Calif). GAPDH was
used to verify all protein loads and normalize data.
Isolation and Cell Culture
Pulmonary vein samples from piglets and humans were minced and
washed with phosphate-buffered saline. Cell isolation was performedrdiovascular Surgery c Volume 148, Number 1 247
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Dwith 5% trypsin and 1 mg/mL type II collagenase in 20% glucose
phosphate-buffered saline at 37C (pH 7.4). After isolation, the cells
were cultured in Iscove modified Dulbecco medium (Life Technologies,
Carlsbad, Calif) with antibiotics and incubated in 5%CO2 at 37
C. Human
umbilical vein endothelial cells (HUVECs) were purchased from ATCC
(Manassas, Va) and cultured.
Cultured human PV cells from a heart transplant donor, banded piglet
PV cells, and HUVECs were treated with 5 ng/mL recombinant human
TGF-b1 (R&D Systems Inc, Minneapolis, Minn) for 48 hours to mimic
the EndMT process.15 Cells that were not treated with TGF-b1 served as
controls. Then, 96- or 384-well plates were used to grow, stain, image,
and analyze cells in a semiautomated manner using HCI to increase
reliability and statistical significance. Immunofluorescence was performed
using the fibronectin (1:100) and a-SMA (1:100) antibodies. Nuclei were
stained with Hoechst (13). Samples were imaged in a Cellomics VTI
automated high-content imager and analyzed using a combination of Image
J and custom-written software. For all 3 cell types, more than 400 cells per
condition were tested, in triplicate.
Statistical Analysis
Continuous variables were expressed as mean  SEM. The unpaired
t test was used for comparisons in echocardiographic data, Western blot
analysis data, and intimal thickness data between the banded and sham
groups. Multiple group comparisons between sham, banded, and stented
groups were compared by 1-way analysis of variance, followed by the
Tukey post hoc test. HCI statistics were generated using custom scripts
written for the R software package (Vienna, Austria) and represented as
Winsorized means (5% tails), and P values were calculated by
Mann-Whitney test.RESULTS
Human PVS Induces a Decrease in Endothelial and
Gain of Mesenchymal Markers in the Hyperplastic
Intima
Histology staining in PV tissues from patients with pro-
gressive PVS demonstrated fibromuscular hyperplasia in the
intima of the pulmonary veins (Figure 1,A) and arterialization
of a pulmonary vein with marked luminal narrowing
(Figure 1, B). In the patient with obstructed TAPVD, immu-
nofluorescence showed that the pulmonary veins had greater
expression of fibronectin anda-SMA, had diminished expres-
sion of CD31 and vWF, and exhibited stronger TGF-b1
expression compared with control human pulmonary veins
(Figure 1, C-L). The loss of endothelial markers and gain of
mesenchymal markers indicated a possible phenotypic
conversion of the endothelium into reparativemyofibroblasts.Banding of the Pulmonary Veins Reproduces
Functional Consequences of Human PVS in a Porcine
Model
Six weeks postbanding, echocardiography demonstrated
that the pulmonary vein gradient increased progressively to
11.50 4.76 mm Hg in the banded animals (vs 3.40 3.36
mm Hg in the sham group; P<.01).
Consistentwith PVS in human patients, banding of porcine
pulmonary veins induced changes in hemodynamics. At 7
weeks postprocedure, banded piglets had equivalent central
venous pressure (4.83 4.08 vs 1.83 1.47 mmHg), higher248 The Journal of Thoracic and Cardiovascular Surgpulmonary capillary wedge pressure (11.33 3.07 vs 5.33
2.14 mm Hg; P ¼ .01), systolic right ventricular pressure
(38.8  8.77 vs 19.50  2.43 mm Hg; P<.01), and mean
pulmonary arterial pressure (34.3  8.89 vs 12.0  2.37
mm Hg; P<.01) compared with sham animals. The ratio of
mean pulmonary arterial pressure to mean systemic blood
pressure was higher in banded piglets than in sham piglets
(0.65 0.18 vs 0.23 0.02mmHg;P<.01). Cardiac output
was not different between groups (0.14 0.02 vs 0.15 0.02
L/min per kg;P¼ .25). Banded piglets had higher pulmonary
vascular resistance (7.54 2.91 vs 1.44 0.24mmHg/L per
minute; P<.01) and lower pulmonary vascular compliance
(1.45  1.11 vs 7.20 1.57 mL/mm Hg; P<.01).
Banded piglets had more right ventricle (RV) hypertro-
phy compared with sham animals, as assessed by the ratio
of right ventricular weight to left ventricular plus ventricu-
lar septal weight (RV/LV þ septum, 0.65  0.10 vs 0.35 
0.02; P ¼ .01). Histologic and morphologic analysis
demonstrated RV hypertrophy manifested with a greater
average diameter of RV myocytes in the banded group
(16.67  1.12 vs 13.95  1.80 mm; P ¼ .02) and a higher
percentage of collagen deposition in the RV of the banded
group compared with the sham group (7.96%  2.66%
vs 2.88%  1.02%; P ¼ .01).
Stent implantation in a single pulmonary vein at 3 weeks
after banding did not improve overall hemodynamics. There
were no significant differences in any hemodynamic
parameters when comparing stented with nonstented
banded piglets 7 weeks postbanding.
Banding of Porcine Pulmonary Veins Mimics the
Intimal Morphologic Changes Observed in Human
PVS
Morphologic changes in upstream pulmonary veins from
the banded piglets were analyzed. These veins had greater
intimal thickness compared with sham piglets (15.48% 
8.76% vs 3.07% 1.04%; P<.01) (Figure 1,M-P). Small
pulmonary veins in the distal lung parenchyma had greater
intimal hyperplasia and luminal stenosis compared with
sham piglets (Figure 1, Q and R). Next, we assessed fibro-
proliferative changes in upstream banded pulmonary veins
by immunofluorescence and Western blotting. Compared
with sham piglets, the upstream pulmonary veins in banded
piglets had greater expression of the mesenchymal markers,
fibronectin and FSP-1, and myofibroblast marker, a-SMA
(Figure 2, A-F). Western blot analysis confirmed greater
expression of a-SMA in upstream banded pulmonary veins
compared with sham piglets (a-SMA/GAPDH, 1.03 0.26
vs 1.38  0.26; P ¼ .028; Figure 2).
To test whether fibroproliferative changes affected
distribution and expression of endothelial markers, we immu-
nostained for CD31, vWF, andVE-cadherin. Expression of all
endothelialmarkers decreased in upstreambanded pulmonary
veins (Figure 2, G-L), similar to the changes seen in humanery c July 2014
FIGURE 2. Representative gain of mesenchymal and decrease of endothelial markers in immunofluorescent staining of upstream pulmonary veins of the
piglet pulmonary vein stenosis (PVS) model. A-C, G, and I, Upstream pulmonary veins in the sham group. D-F and J-L, Upstream pulmonary veins in the
banded group. Banded pulmonary veins exhibited greater expression ofmesenchymalmarkers (fibronectin, fibroblast-specific protein [FSP]-1, anda-smooth
muscle actin [SMA] in A-F; 4003magnification) and less expression of endothelial markers (CD31, von Willebrand factor [vWF], and vascular endothelial
[VE]-cadherin inG-L; 4003magnification) comparedwith shampulmonary veins. The banded upstreampulmonary vein demonstrated increased expression
of a-SMA and decreased expression of CD31 and VE-cadherin in Western blot analysis. GAPDH, Glyceraldehyde-3-phosphate dehydrogenase. *P<.05.
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DPVS samples (Figure 1). Western blotting confirmed lower
expression of the endothelial markers, CD31 and VE-
cadherin, in banded piglet pulmonary veins (CD31/GAPDH,
0.20  0.08 vs 0.10  0.07 [P ¼ .031]; and VE-cadherin/
GAPDH, 2.42  0.58 vs 1.72  0.36 [P ¼ .017]) (Figure 2).
Double immunostaining of CD31 and a-SMAwas performed
to investigate the pathologic process associatedwith transition
of individual cells with coexpression of endothelial and
mesenchymal markers. Imaging revealed intermittent intimal
cells coexpressing endothelial and mesenchymal markers in
banded pulmonary veins (transitional cell phenotype)
(Figure 3, G). Coexpression of these markers was never
observed in pulmonary veins of sham animals.Intimal Hyperplasia After Pulmonary Vein Banding
Is Associated With Profibrotic Signaling Events
One of the major drivers of EndMT is TGF-b-mediated
signaling events that involve phosphorylation andThe Journal of Thoracic and Casubsequent nuclear translocation of Smad.16,17 Expression
of TGF-b1 in the pulmonary veins was greater in banded
compared with sham piglets, consistent with the presence
of EndMT (Figure 3, H and I). Quantitatively, Western
blot analysis demonstrated increased expression of TGF-
b1 and Smad 4 in banded upstream PVs compared with un-
banded PVs (TGF-b1/GAPDH, 1.15  0.32 vs 1.73  0.34
[P ¼ .01]; Smad 4/GAPDH, 0.50  0.15 vs 0.76  0.24
[P ¼ .05]; Figure 3).Stent Implantation Partially Reverses the Changes
Induced by Experimental PVS
In-stent restenosis reduced the luminal diameter within
the stent by 43% 28% at 4 weeks after stent implantation
in the porcine model (Figure 4, K). At 7 weeks after
pulmonary vein banding (4 weeks after stent implantation),
upstream pulmonary veins in the stented piglets demon-
strated greater expression of TGF-b1 in comparison tordiovascular Surgery c Volume 148, Number 1 249
FIGURE 3. Coexpression of endothelial and mesenchymal markers confirming the presence of the endothelial-mesenchymal transition (EndMT)
transitional cell phenotype. A-C, H, and I, Upstream pulmonary veins in the sham group. D-G, J, and K, Upstream pulmonary veins in the banded group.
A-F, Immunofluorescence showed decreased endothelial and increased mesenchymal markers in banded pulmonary veins. G, In the banded group, intimal
cells expressed an endothelial marker (CD31 in red) in the outer membrane and a mesenchymal marker (a-smooth muscle actin [SMA] in green) in the
intracellular space, consistent with an EndMT transitional cell (6003magnification). H and I, Expression of transforming growth factor (TGF)-b1. Banded
pulmonary veins demonstrated greater expression of TGF-b1 compared with sham pulmonary veins (4003magnification). Western blot analysis supported
increased expression of TGF-b1 and Smad 4 in banded upstream pulmonary veins (P ¼ .01 and P ¼ .049, respectively). Asterisks refer to statistically
significant comparisons. GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; S, sham; B, banded.
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Dsham animals but less expression than banded animals (by
subjective evaluation of immunofluorescence images).
These findings suggested partial down-regulation of
TGF-b expression and partial reappearance of CD31 and
vWF (endothelial marker) expression with enhanced and
localized fibronectin and a-SMA (mesenchymal and
myofibroblast markers) expression in the intima (Figure 4,
A-L), consistent with partial reversal of the immunohisto-
chemical features of EndMT.
Three Types of Cultured Cells Are Prone to
Experimentally Induced EndMT
All 3 cultured cell types (banded piglet PV cells, human
control PV cells, and HUVECs) demonstrated increased
expression of the myofibroblast markers, fibronectin and
a-SMA, after TGF-b1 exposure (integrated fluorescence in-
tensity, fibronectin: piglet cells, 1008  89 vs 1044  120
[P < .05]; human cells, 3918  111 vs 4836  123
[P < .05]; HUVECs, 1418  102 vs 2160  176
[P< .01]; a-SMA: piglet cells, 3679  167 vs 5935 
400 [P < .01]; HUVECs, 1882  160 vs 2072  189250 The Journal of Thoracic and Cardiovascular Surg[P< .05]; Figure 5). The increase in the myofibroblast
markers suggests that stimulation with TGF-b1 recapitu-
lates the pathologic process observed in the in vivo animal
model.
DISCUSSION
We previously investigated a piglet model of progressive
PVS, which revealed increased pulmonary vascular
resistance and degradation of the internal elastic lamina of
the pulmonary veins.10 The precise molecular pathways
leading to the pulmonary venous fibrogenic response,
however, remain unknown. The piglet model described
herein recapitulates the critical aspects of clinical PVS,
including myocardial alterations, hemodynamic sequelae,
and histopathologic features, in the affected pulmonary
veins. Examination of the cellular response in upstream
pulmonary veins reveals a decrease of endothelial markers
and a gain of mesenchymal markers, implicating a potential
role for EndMT in the pathologic process. EndMT has also
been observed to participate in several other fibrogenic
diseases in which vascular remodeling is a criticalery c July 2014
FIGURE 4. Representative immunofluorescent staining and hematoxylin and eosin (HE) staining of stented piglet pulmonary veins. A-E, Upstream
pulmonary veins in the stented group. F-J, Upstream pulmonary veins in the banded group. Upstream pulmonary veins from stented piglets demonstrated
moderately increased transforming growth factor (TGF)-b1 expression, regained endothelial markers (B and C), and strong expression of mesenchymal
markers (D and E). K, Representative HE staining of pulmonary veins with a stent from a stented piglet demonstrated in-stent restenosis. Arrow indicates
stent fragments inside the pulmonary venous wall (503magnification). A graph below showed the percentage of in-stent restenosis 4 weeks poststenting in
each stent area. Average area percentage of in-stent stenosis was 43.46%  27.85%. vWF, Von Willebrand factor; SMA, smooth muscle actin.
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Dcomponent of the pathologic process.15,18-20 Other data
suggesting a role for EndMT in the pathology include the
finding of coexpression of endothelial and mesenchymal
markers in the pulmonary vein intimal cells of banded
piglets, albeit at low frequency. The presence of such
coexpression has been cited as supportive evidence for the
intermediate stage of EndMT.18,21,22 In the current study,
increased TGF-b and Smad 4 expression were also notedFIGURE 5. Induction of endothelial-mesenchymal transition (EndMT) in vitro
umbilical vein endothelial cells (HUVECs). A and C, Control banded piglet p
transforming growth factor (TGF)-b1 (5 ng/mL, 24 hours). E and G, Control
The cells treated with TGF-b1 showed an increase in the myofibroblast mark
transitional process (P<.05 vs control).
The Journal of Thoracic and Cain the obstructed PVs from piglets. TGF-b is a well-
known mediator of EndMT during cardiovascular develop-
ment.15,23-25 Smad is a downstream mediator in the TGF-b
signaling pathways, with Smad 4 a common mediator
interacting with receptor-regulated Smads, which, in turn,
is associated with EndMT.19,26-28
Although local inflammation at the banding site may
have a role in diffuse PVS, these data suggest that upstreamhigh-content imaging of cultured piglet pulmonary vein cells and human
ulmonary vein (PV) cells. B and D, Banded piglet PV cells treated with
HUVECs. F and H, HUVECs treated with TGF-b1 (5 ng/mL, 24 hours).
ers, fibronectin and a-smooth muscle actin (SMA), capturing the EndMT
rdiovascular Surgery c Volume 148, Number 1 251
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elaboration of TGF-b, Smad signaling events, and prolifer-
ation of myofibroblasts in the pulmonary vein wall. Local
inflammation from the banding material does, however,
represent a limitation of our model. We have attempted
to mitigate this limitation by examining the ‘‘upstream’’
pulmonary veins at locations that were 10 to 40 mm away
from the banding site. We believe this distance is beyond
the range of local inflammation. Although difficult to
precisely identify, the geometric extent of the local inflam-
matory effect, the examined upstream areas, appeared
on gross inspection to be free of obvious induration.
Furthermore, our histologic examination was consistent
with human samples in which there were no implanted
foreign bodies to create PVS.
Although our data were consistent with a role for
EndMT in the observed pulmonary venous pathology, other
mechanisms alone or in combination with EndMT may
account for the fibrogenic response in the upstream pulmo-
nary veins. The increased number of myofibroblasts may be
derived from proliferation of local or migrating resident
mesenchymal cells29,30 or may originate from circulating
progenitor cells.31,32 We propose that, irrespective of its
putative origin, however, the myofibroblast is the culprit
cell in the pathogenesis of PVS.
The use of high-content imaging in the present study
demonstrates that TGF-b induces a myofibroblast pheno-
type in human and piglet pulmonary veins and in HUVECs.
We propose that this cell-based assay, suitable for high-
throughput screening, emulates a critical element in the
genesis of PVS and could be used to evaluate libraries of
compounds for their capacity to inhibit this process.
This would advance the objective of developing therapeutic
agents designed to target TGF-b1–mediated transformation
and the disease-relevant molecular pathways leading
to PVS.
Few studies have evaluated the effect of stent implanta-
tion in obstructed pulmonary veins, and these studies tend
to focus on in-stent restenosis rather than the histopathology
of the upstream pulmonary veins. Indeed, we noted signi-
ficant in-stent restenosis within 4 weeks of stent placement,
which is consistent with the limited efficacy of stents to treat
pediatric PVS.9 Furukawa and colleagues13 evaluated the
effectiveness of drug-eluting stents in pig pulmonary veins.
However, in their study, the stents were deployed in
unobstructed pulmonary veins. In contrast, our report is
the first, to our knowledge, to evaluate the efficacy of stents
in a model of progressive PVS. Future studies to test the
efficacy of stents may be more informative if performed
in the setting of an experimental model of PVS. The piglet
model is a ‘‘high-yield’’ model because there is ample
opportunity to study mechanisms of upstream PVS,
in-stent restenosis, and right ventricular failure due to
pressure overload (beyond the scope of the current article).252 The Journal of Thoracic and Cardiovascular SurgDespite the temporary reduction of obstruction, upstream
pulmonary veins responded to stent implantation with some
return of endothelial markers, suggesting the potential for
plasticity in the observed pathophysiologic process.
Reversal of EndMT is known to occur (ie, mesenchymal-
endothelial transition).33 Stenting appears to have initiated
some reversal of the process, possibly because of temporary
relief of local pulmonary venous hypertension. Rapid
in-stent restenosis, however, likely limited the efficacy of
the intervention. We need to study more time points after
stent implantation to better characterize the alterations in
pulmonary venous pathology associated with relief of
obstruction. The origin of the cells expressing endothelial
markers after stenting is unclear, and these cells could
arise from mesenchymal-endothelial transition, circulating
endothelial progenitor cells,34,35 or enhanced reexpression
from native endothelial cells. Although the mechanism is
unclear, the potential for reversibility of the pathologic
process warrants further investigation to develop novel
adjuvant therapies designed to promote reversal of the
process in concert with local surgical and stent-based
decompression of pulmonary vein stenosis.
We thank Wei Hui from Heart Centre Echocardiography
Laboratory for performing echocardiography and appreciate the
contribution of participating surgeons, Drs Glen Van Arsdell,
Osami Honjo, and Edward Hickey.
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